+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Epilepsy Drugs Market Size, Share & Trends Analysis Report by Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics), Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
Epilepsy Drugs Market Size, Share & Trends Analysis Report by Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics), Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
New

Epilepsy Drugs Market Size, Share & Trends Analysis Report by Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 90 Pages
  • February 2025
  • Region: Global
  • Grand View Research
  • ID: 5921034
Description Jump to:
The Epilepsy Drugs Market was valued at USD 11.13 billion in 2024, and is projected to reach USD 15.47 billion by 2030, rising at a CAGR of 5.70%. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness trainingto the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Epilepsy Drugs Market Report Highlights

  • Second generation anti-epileptics are expected to be the second-fastest-growing segment. This segment includes Lamotrigine (Lamictal), Levetiracetam (Keppra), Brivaracetam (Briviact), and Perampanel (Fycompa).
  • The third generation anti-epileptics segment accounted for the largest revenue share of around 39.7% in 2024. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
  • North America dominated the market with the largest revenue share of around 38.7% in 2024. The high prevalence of epilepsy in the region, with a significant number of people affected by the condition, is a major driving factor for the epilepsy drugs market.
  • Asia Pacific epilepsy drugs market is expected to register at a notable CAGR over the forecast period, attributed to the large and diverse population of the region, surging prevalence of epilepsy, and improving healthcare infrastructure.

This report addresses:

  • Market intelligence to enable effective decision-making.
  • Market estimates and forecasts from 2018 to 2030.
  • Growth opportunities and trend analyses.
  • Segment and regional revenue forecasts for market assessment.
  • Competition strategy and market share analysis.
  • Product innovation listings for you to stay ahead of the curve.
  • COVID-19's impact and how to sustain in this fast-evolving market.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment
1.2.2. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Epilepsy Drugs Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTLE Analysis
Chapter 4. Epilepsy Drugs Market: Treatment Business Analysis
4.1. Treatment Market Share, 2024 & 2030
4.2. Treatment Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
4.4. First Generation Anti-epileptics
4.4.1. First Generation Anti-epileptics Market, 2018-2030 (USD Million)
4.5. Second Generation Anti-epileptics
4.5.1. Second Generation Anti-epileptics Market, 2018-2030 (USD Million)
4.6. Third Generation Anti-epileptics
4.6.1. Third Generation Anti-epileptics Market, 2018-2030 (USD Million)
Chapter 5. Epilepsy Drugs Market: Distribution Channel Business Analysis
5.1. Distribution Channel Market Share, 2024 & 2030
5.2. Distribution Channel Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
5.4. Hospital Pharmacies
5.4.1. Hospital Pharmacies Market, 2018-2030 (USD Million)
5.5. Retail Pharmacies
5.5.1. Retail Pharmacies Market, 2018-2030 (USD Million)
5.6. Others
5.6.1. Others Market, 2018-2030 (USD Million)
Chapter 6. Epilepsy Drugs Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. North America Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Regulatory Framework
6.4.2.3. Competitive Insights
6.4.2.4. U.S. Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Regulatory Framework
6.4.3.3. Competitive Insights
6.4.3.4. Canada Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Regulatory Framework
6.4.4.3. Competitive Insights
6.4.4.4. Mexico Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5. Europe
6.5.1. Europe Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.2. U.K.
6.5.2.1. Key Country Dynamics
6.5.2.2. Regulatory Framework
6.5.2.3. Competitive Insights
6.5.2.4. U.K. Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Regulatory Framework
6.5.3.3. Competitive Insights
6.5.3.4. Germany Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Regulatory Framework
6.5.4.3. Competitive Insights
6.5.4.4. France Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Regulatory Framework
6.5.5.3. Competitive Insights
6.5.5.4. Italy Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Regulatory Framework
6.5.6.3. Competitive Insights
6.5.6.4. Spain Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Regulatory Framework
6.5.7.3. Competitive Insights
6.5.7.4. Denmark Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.8. Norway
6.5.8.1. Key Country Dynamics
6.5.8.2. Regulatory Framework
6.5.8.3. Competitive Insights
6.5.8.4. Norway Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.9. Sweden
6.5.9.1. Key Country Dynamics
6.5.9.2. Regulatory Framework
6.5.9.3. Competitive Insights
6.5.9.4. Sweden Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Regulatory Framework
6.6.2.3. Competitive Insights
6.6.2.4. Japan Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Regulatory Framework
6.6.3.3. Competitive Insights
6.6.3.4. China Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Regulatory Framework
6.6.4.3. Competitive Insights
6.6.4.4. India Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.5. South Korea
6.6.5.1. Key Country Dynamics
6.6.5.2. Regulatory Framework
6.6.5.3. Competitive Insights
6.6.5.4. South Korea Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamics
6.6.6.2. Regulatory Framework
6.6.6.3. Competitive Insights
6.6.6.4. Australia Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Regulatory Framework
6.6.7.3. Competitive Insights
6.6.7.4. Thailand Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Regulatory Framework
6.7.2.3. Competitive Insights
6.7.2.4. Brazil Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Regulatory Framework
6.7.3.3. Competitive Insights
6.7.3.4. Argentina Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Regulatory Framework
6.8.2.3. Competitive Insights
6.8.2.4. South Africa Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Regulatory Framework
6.8.3.3. Competitive Insights
6.8.3.4. Saudi Arabia Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Regulatory Framework
6.8.4.3. Competitive Insights
6.8.4.4. UAE Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Regulatory Framework
6.8.5.3. Competitive Insights
6.8.5.4. Kuwait Epilepsy Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. UCB S.A.
7.5.1.1. Participant’s Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Sanofi
7.5.2.1. Participant’s Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Pfizer, Inc.
7.5.3.1. Participant’s Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Otsuka America Pharmaceutical, Inc.
7.5.4.1. Participant’s overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Eisai Co., Ltd.
7.5.5.1. Participant’s Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Abbott Laboratories, Inc.
7.5.6.1. Participant’s Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Novartis AG
7.5.7.1. Participant’s Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. GlaxoSmithKline plc
7.5.8.1. Participant’s Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Sunovion Pharmaceuticals, Inc.
7.5.9.1. Participant’s Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Jazz Pharmaceuticals plc
7.5.10.1. Participant’s Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
7.5.11. Neurelis, Inc.
7.5.11.1. Participant’s Overview
7.5.11.2. Financial Performance
7.5.11.3. Product Benchmarking
7.5.11.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Epilepsy Drugs Market, by Region, 2018-2030 (USD Million)
Table 4 Global Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 5 Global Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 6 North America Epilepsy Drugs Market, by Country, 2018-2030 (USD Million)
Table 7 North America Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 8 North America Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 9 U.S. Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 10 U.S. Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 11 Canada Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 12 Canada Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 13 Mexico Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 14 Mexico Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 15 Europe Epilepsy Drugs Market, by Country, 2018-2030 (USD Million)
Table 16 Europe Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 17 Europe Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 18 U.K. Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 19 U.K. Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 20 Germany Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 21 Germany Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 22 France Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 23 France Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 24 Italy Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 25 Italy Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 26 Spain Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 27 Spain Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 28 Denmark Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 29 Denmark Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 30 Norway Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 31 Norway Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 32 Sweden Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 33 Sweden Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 34 Asia Pacific Epilepsy Drugs Market, by Country, 2018-2030 (USD Million)
Table 35 Asia Pacific Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 36 Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 37 Japan Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 38 Japan Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 39 China Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 40 China Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 41 India Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 42 India Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 43 South Korea Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 44 South Korea Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 45 Australia Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 46 Australia Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 47 Thailand Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 48 Thailand Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 49 Latin America Epilepsy Drugs Market, by Country, 2018-2030 (USD Million)
Table 50 Latin America Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 51 Latin America Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 52 Brazil Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 53 Brazil Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 54 Argentina Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 55 Argentina Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 56 Middle East & Africa Epilepsy Drugs Market, by Country, 2018-2030 (USD Million)
Table 57 Middle East & Africa Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 58 Middle East & Africa Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 59 South Africa Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 60 South Africa Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 61 Saudi Arabia Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 62 Saudi Arabia Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 63 UAE Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 64 UAE Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 65 Kuwait Epilepsy Drugs Market, by Treatment, 2018-2030 (USD Million)
Table 66 Kuwait Epilepsy Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Epilepsy Drugs Market Segmentation
Figure 2 Market Research Process
Figure 3 Data Triangulation Techniques
Figure 4 Primary Research Pattern
Figure 5 Market Research Approaches
Figure 6 Value-Chain-Based Sizing & Forecasting
Figure 7 Market Formulation & Validation
Figure 8 Market Snapshot
Figure 9 Treatment and Distribution Channel Outlook (USD Million)
Figure 10 Competitive Landscape
Figure 11 Epilepsy Drugs Market Dynamics
Figure 12 Epilepsy Drugs Market: Porter’s Five Forces Analysis
Figure 13 Epilepsy Drugs Market: PESTLE Analysis
Figure 14 Epilepsy Drugs Market: Treatment Segment Dashboard
Figure 15 Epilepsy Drugs Market: Treatment Market Share Analysis, 2024 & 2030
Figure 16 First Generation Anti-epileptics Market, 2018-2030 (USD Million)
Figure 17 Second Generation Anti-epileptics Market, 2018-2030 (USD Million)
Figure 18 Third Generation Anti-epileptics Market, 2018-2030 (USD Million)
Figure 19 Epilepsy Drugs Market: Distribution Channel Segment Dashboard
Figure 20 Epilepsy Drugs Market: Distribution Channel Market Share Analysis, 2024 & 2030
Figure 21 Hospital Pharmacies Market, 2018-2030 (USD Million)
Figure 22 Retail Pharmacies Market, 2018-2030 (USD Million)
Figure 23 Others Market, 2018-2030 (USD Million)
Figure 24 Epilepsy Drugs Market Revenue, by Region
Figure 25 Regional Marketplace: Key Takeaways
Figure 26 Regional Marketplace: Key Takeaways
Figure 27 North America Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 28 U.S. Country Dynamics
Figure 29 U.S. Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 30 Canada Country Dynamics
Figure 31 Canada Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 32 Mexico Country Dynamics
Figure 33 Mexico Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 34 Europe Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 35 U.K. Country Dynamics
Figure 36 U.K. Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 37 Germany Country Dynamics
Figure 38 Germany Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 39 France Country Dynamics
Figure 40 France Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 41 Italy Country Dynamics
Figure 42 Italy Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 43 Spain Country Dynamics
Figure 44 Spain Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 45 Denmark Country Dynamics
Figure 46 Denmark Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 47 Norway Country Dynamics
Figure 48 Norway Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 49 Sweden Country Dynamics
Figure 50 Sweden Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 51 Asia Pacific Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 52 Japan Country Dynamics
Figure 53 Japan Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 54 China Country Dynamics
Figure 55 China Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 56 India Country Dynamics
Figure 57 India Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 58 South Korea Country Dynamics
Figure 59 South Korea Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 60 Australia Country Dynamics
Figure 61 Australia Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 62 Thailand Country Dynamics
Figure 63 Thailand Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 64 Latin America Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 65 Brazil Country Dynamics
Figure 66 Brazil Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 67 Argentina Country Dynamics
Figure 68 Argentina Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 69 Middle East & Africa Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 70 South Africa Country Dynamics
Figure 71 South Africa Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 72 Saudi Arabia Country Dynamics
Figure 73 Saudi Arabia Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 74 UAE Country Dynamics
Figure 75 UAE Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 76 Kuwait Key Country Dynamicss
Figure 77 Kuwait Epilepsy Drugs Market, 2018-2030 (USD Million)
Figure 78 Company Categorization
Figure 79 Company Market Position Analysis
Figure 80 Strategic Framework

Companies Mentioned

The major companies profiled in this Epilepsy Drugs market report include:
  • UCB S.A.
  • Sanofi
  • Pfizer, Inc.
  • Otsuka America Pharmaceutical, Inc.
  • Eisai Co., Ltd.
  • Abbott Laboratories, Inc.
  • Novartis AG
  • GlaxoSmithKline plc
  • Sunovion Pharmaceuticals, Inc.
  • Jazz Pharmaceuticals plc
  • Neurelis, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages90
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 11.13 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.47 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Epilepsy Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Epilepsy Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Epilepsy Drugs Market by Generation Type, Anti-Epileptics Drugs Type, Distribution Channel, and Region 2025-2033 - Product Image

Epilepsy Drugs Market by Generation Type, Anti-Epileptics Drugs Type, Distribution Channel, and Region 2025-2033

  • Report
  • 135 Pages
  • Global
From
Global Epilepsy Drugs Market Report 2024 - Product Image

Global Epilepsy Drugs Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Epilepsy Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Epilepsy Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 240 Pages
  • Global
From
Epilepsy Drug Market by Product Type, Distribution Channel - Global Forecast 2025-2030 - Product Image

Epilepsy Drug Market by Product Type, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.